Zura Bio stock jumps on plans to raise $112.5M in private financing
https://seekingalpha.com/news/4091083-zura-bio-stock-jumps-on-plans-to-raise-1125m-in-private-financing?source=feed_sector_healthcare
Apr 18, 2024 - Zura Bio (ZURA) shares jumped around 12% after the immunology company entered into subscription agreements for a private placement.
0
Bio-Rad Laboratories (BIO) to Post Q1 Earnings: What Awaits?
https://www.zacks.com/stock/news/2257849/bio-rad-laboratories-bio-to-post-q1-earnings-what-awaits?cid=CS-ZC-FT-analyst_blog|earnings_preview-2257849
Apr 18, 2024 - The ongoing weakness in the biopharma end markets and tightening of sanctions against Russia is likely to have hurt Bio-Rad's (BIO) first-quarter 2024 growth.
0
2seventy bio (TSVT) Rises More Than 50% in 3 Months: Here's Why
https://www.zacks.com/stock/news/2257012/2seventy-bio-tsvt-rises-more-than-50-in-3-months-here-s-why?cid=CS-ZC-FT-analyst_blog|price_surge_/_plunge-2257012
Apr 17, 2024 - The FDA's recent nod to 2seventy bio's (TSVT) Abecma in earlier lines of treatment for relapsed/refractory multiple myeloma is a positive. Also, the R&D asset divestiture to Regeneron is saving costs.
0
Mustang Bio stock tumbles 27% amid news of mass layoffs
https://seekingalpha.com/news/4089763-mustang-bio-stock-tumbles-amid-news-of-mass-layoffs?source=feed_sector_healthcare
Apr 15, 2024 - Mustang Bio (MBIO) stock tumbled 27% Monday in the wake of news that the company plans to cut around 81% of its workforce to conserve cash. Read more here.
0
Is Bluebird Bio Stock a Buy?
https://www.fool.com/investing/2024/04/15/is-bluebird-bio-stock-a-buy/?source=iedfolrf0000001
Apr 15, 2024 - This small biotech is struggling to fly -- and investors should probably steer clear.
0
Better Buy: Bluebird Bio Vs. Novavax
https://www.fool.com/investing/2024/04/13/better-buy-bluebird-bio-vs-novavax/?source=iedfolrf0000001
Apr 13, 2024 - Who wins this face-to-face between two beaten-down biotechs?
0
Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year?
https://www.zacks.com/stock/news/2254517/is-entera-bio-entx-outperforming-other-medical-stocks-this-year?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_1-2254517
Apr 12, 2024 - Here is how Entera Bio Ltd. (ENTX) and FibroGen (FGEN) have performed compared to their sector so far this year.
0
Jefferies cuts Instil Bio to hold, cites drug discontinuation
https://seekingalpha.com/news/4089263-jefferies-cuts-instill-bio-to-hold-cites-drug-discontinuation?source=feed_sector_healthcare
Apr 12, 2024 - Jefferies downgraded Instil Bio (TIL) to hold, citing discontinuation of clinical development for the company’s drug candidate ITIL-306.
0
Bruker Offers Upside With Key Enabling Technologies For Future Bio-Pharma Research
https://seekingalpha.com/article/4683358-bruker-offers-upside-with-key-enabling-technologies-for-future-bio-pharma-research?source=feed_all_articles
Apr 11, 2024 - Bruker offers growth at reasonable price for investors and is well-positioned for healthy revenue growth in 2024. Find out why BRKR stock is a Buy.
0
Oppenheimer starts Q32 Bio at outperform, cites lead asset
https://seekingalpha.com/news/4088992-oppenheimer-starts-q32-bio-at-outperform-cites-lead-asset?source=feed_sector_healthcare
Apr 11, 2024 - Oppenheimer started coverage of Q32 Bio (QTTB) with an outperform rating, citing the market potential of the company’s lead drug asset, bempikibart. Read more here.
0